Seattle Genetics, Inc. (NASDAQ:SGEN)

CAPS Rating: 3 out of 5

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

Recs

0
Player Avatar Biotoday (31.51) Submitted: 10/7/2010 11:21:23 AM : Outperform Start Price: $16.25 SGEN Score: +12.56

Just gets better.

Report this Post Reply

Featured Broker Partners


Advertisement